GREATWALL KINASE
Targeted Greatwall Kinase Blockade Offers A Novel Strategy for Chemoprevention
| Coordinatore | UNIVERSITY OF SUSSEX
Organization address
address: Sussex House contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 209˙033 € |
| EC contributo | 209˙033 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2011-IIF |
| Funding Scheme | MC-IIF |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-09-01 - 2014-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF SUSSEX
Organization address
address: Sussex House contact info |
UK (FALMER, BRIGHTON) | coordinator | 209˙033.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
The progression of cells through mitosis is tightly regulated to ensure the integrity of chromosomal transmission and cell division. The proper orchestration of mitotic progression is controlled by the balanced activity of mitotic kinases and counteracting phosphatases. Misregulation of these controls can be detrimental causing loss of entire chromosomes and aneuploidy. Considering that mitotic kinases are only expressed in actively dividing cells, targeting these kinases for cancer management is highly desirable. To this end, we are validating the mitotic kinase Greatwall Kinase (Greatwall) as a target for cancer therapy. Initial studies show that siRNA knockdown of Greatwall leads to rapid cell death in a number of transformed cell lines. Surprisingly, we found that untransformed RPE cells with low Greatwall protein and mRNA levels remained unaffected after Greatwall knock down. Moreover, Greatwall levels fluctuate dramatically among different cancer cell lines and are generally low in non-transformed tissues. Seminal studies using Xenopus egg extracts and drosophila larvae show that Greatwall has an important role in the cell cycle control of rapidly dividing embryonic cells and it is possible that some tumor cells have reverted back to this state of dependency on Greatwall. This makes Greatwall even more promising as an anti-cancer agent as its activity is dispensable in somatic cells but critical to the survival and proliferation of cancer cells. In light of these findings, I aim to pursue target validation studies with Greatwall, elucidate synergistic effects using known mitotic kinase inhibitors, and work closely with a team of medicinal chemists to characterize novel small-molecule Greatwall modulators. Nonspecific interactions between known mitotic kinase inhibitors and normally dividing cells often lead to unwanted side-effects. Targeting Greatwall provides an opportunity to circumvent this undesirable outcome and advance translational research.